Wall Street Zen upgraded shares of Obsidian Therapeutics (NASDAQ:OBX – Free Report) to a sell rating in a research report released on Saturday morning,Wall Street Zen reports.
Several other analysts also recently issued reports on OBX. Zacks Research raised Obsidian Therapeutics to a “hold” rating in a report on Thursday, August 6th. Weiss Ratings assumed coverage on Obsidian Therapeutics in a research note on Wednesday, September 2nd. They set a “sell (d-)” rating for the company. Lifesci Capital initiated coverage on Obsidian Therapeutics in a research report on Tuesday, August 18th. They issued an “outperform” rating and a $43.00 target price on the stock. Piper Sandler started coverage on Obsidian Therapeutics in a research note on Wednesday, August 5th. They issued an “overweight” rating and a $42.00 target price on the stock. Finally, William Blair began coverage on shares of Obsidian Therapeutics in a report on Wednesday, September 9th. They set an “outperform” rating for the company. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Obsidian Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $42.50.
View Our Latest Stock Report on Obsidian Therapeutics
Obsidian Therapeutics Stock Performance
About Obsidian Therapeutics
Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered TIL cell therapies for the treatment of patients with solid tumors. Obsidian Therapeutics Inc is based in CAMBRIDGE, Mass.
Featured Stories
- Five stocks we like better than Obsidian Therapeutics
- Can Bloom Energy Pop the Top Off AI’s Massive Energy Bottleneck?
- Coach’s Momentum Powers Tapestry Despite the Stock’s Sharp Pullback
- AI Is Reshaping SaaS—These 2 Software ETFs Offer Different Ways to Play It
- Insiders Signal Deep Value In DICK’s Sporting Goods
Receive News & Ratings for Obsidian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obsidian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
